Interim 2018/19 influenza vaccine effectiveness: European studies, October 2018 to January 2019

European IVE group

doi:10.2807/1560-7917.ES.2019.24.1900121

Interim 2018/19 influenza vaccine effectiveness: European studies, October 2018 to January 2019

European IVE group

Research output: Contribution to journal › Article › peer-review

66 Citations (Scopus)

Abstract

Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

Original language	English
Article number	1900121
Journal	Eurosurveillance
Volume	24
Issue number	8
DOIs	https://doi.org/10.2807/1560-7917.ES.2019.24.1900121
Publication status	Published - 21 Feb 2019

Bibliographical note

Publisher Copyright:
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Any supplementary material referenced in the article can be found in the online version. This article is copyright of the authors or their affiliated institutions, 2019.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2807/1560-7917.ES.2019.24.1900121

Cite this

@article{8437a74e1e6d4490832bd55cb5d23e77,

title = "Interim 2018/19 influenza vaccine effectiveness: European studies, October 2018 to January 2019",

abstract = "Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43\% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38\% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.",

author = "\{European IVE group\} and Esther Kissling and Angela Rose and Emborg, \{Hanne Dorthe\} and Alin Gherasim and Richard Pebody and Francisco Pozo and Ramona Trebbien and Clara Mazagatos and Heather Whitaker and Marta Valenciano",

note = "Publisher Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Any supplementary material referenced in the article can be found in the online version. This article is copyright of the authors or their affiliated institutions, 2019.",

year = "2019",

month = feb,

day = "21",

doi = "10.2807/1560-7917.ES.2019.24.1900121",

language = "English",

volume = "24",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "8",

}

TY - JOUR

T1 - Interim 2018/19 influenza vaccine effectiveness

T2 - European studies, October 2018 to January 2019

AU - European IVE group

AU - Kissling, Esther

AU - Rose, Angela

AU - Emborg, Hanne Dorthe

AU - Gherasim, Alin

AU - Pebody, Richard

AU - Pozo, Francisco

AU - Trebbien, Ramona

AU - Mazagatos, Clara

AU - Whitaker, Heather

AU - Valenciano, Marta

N1 - Publisher Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Any supplementary material referenced in the article can be found in the online version. This article is copyright of the authors or their affiliated institutions, 2019.

PY - 2019/2/21

Y1 - 2019/2/21

N2 - Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

AB - Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

UR - https://www.scopus.com/pages/publications/85064214543

U2 - 10.2807/1560-7917.ES.2019.24.1900121

DO - 10.2807/1560-7917.ES.2019.24.1900121

M3 - Article

C2 - 30808440

AN - SCOPUS:85064214543

SN - 1025-496X

VL - 24

JO - Eurosurveillance

JF - Eurosurveillance

IS - 8

M1 - 1900121

ER -

Interim 2018/19 influenza vaccine effectiveness: European studies, October 2018 to January 2019

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this